Quinolines and derivatives
Medchemexpress LLC Deucravacitinib | 1609392-27-9 | 99.9% | 425.46 | 200 MG
Deucravacitinib is a highly selective, orally bioavailable allosteric TYK2 inhibitor designed for the treatment of autoimmune diseases. It works by selectively binding to the TYK2 pseudokinase (JH2) domain, which blocks receptor-mediated Tyk2 activation by stabilizing its regulatory JH2 domain. This action inhibits IL-12/23 and type I IFN pathways. It is used for studying moderate to severe plaque psoriasis.
- Highly selective, orally bioavailable allosteric TYK2 inhibitor
- Designed for the treatment of autoimmune diseases
- Selectively binds to the TYK2 pseudokinase (JH2) domain
- Blocks receptor-mediated Tyk2 activation
- Inhibits IL-12/23 and type I IFN pathways
- Used for studying moderate to severe plaque psoriasis
- FDA's first de novo deuterium
Medchemexpress LLC Sitravatinib | 1123837-84-2 | 99.6% | 629.68 | 200 MG
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor that demonstrates potent single-agent antitumor efficacy. It enhances the activity of PD-1 blockade by promoting an antitumor immune microenvironment, making it suitable for various research applications in oncology.
- Orally bioavailable receptor tyrosine kinase (RTK) inhibitor
- Potent single-agent antitumor efficacy
- Enhances PD-1 blockade activity
- Promotes an antitumor immune microenvironment
- Soluble in DMSO for in vitro studies
- Available in solid form for various research needs
Medchemexpress LLC Nilotinib | 641571-10-0 | 99.9% | 529.52 | 200 MG
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity, designed for research use. It exhibits significant inhibitory effects against Bcr-Abl and various other targets, making it suitable for studies on cell proliferation and cytotoxicity.
- Exhibits antiproliferative activity in A549 cells with an IC50 of 6.63 μM.
- Shows antiproliferative activity in BJ cells with an IC50 of 12.8 μM.
- Inhibits various BCR/ABL p210 mutants (GI50 0.004 μM to > 10 μM).
- Induces cytotoxicity against various BaF3 cell lines.
- Used in CCK-8 assays for IC50 assessment in liver cancer cell lines.
- Useful for observing anti-colony formation effects.
- Utilized for immunohistochemistry of primary tumors.
- Investigated for its direct effect on cytotoxic lymphocytes.
- Applied for cell cycle analysis.
Medchemexpress LLC Molnupiravir | 2492423-29-5 | 99.9% | 329.31 | 200 MG
Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. It exhibits broad-spectrum antiviral activity against influenza virus and multiple coronaviruses, including SARS-CoV-2, MERS-CoV, and SARS-CoV. It is being researched for its potential use in COVID-19 and seasonal/pandemic influenza.
- Orally bioavailable prodrug
- Exhibits broad-spectrum antiviral activity
- Effective against SARS-CoV-2, MERS-CoV, and SARS-CoV
- Being researched for use in COVID-19 and influenza
- Prevents SARS-CoV replication in C57BL/6 mice
- Reduces shed virus load and fever duration in ferrets
Medchemexpress LLC Palmitoylethanolamide | 544-31-0 | MFCD00020562 | 99.86% | 299.49 | 200 MG
Palmitoylethanolamide (Standard) is the analytical standard for Palmitoylethanolamide, an active endogenous compound. It is intended for research and analytical applications, and can be used for preventing virus infection of the respiratory tract.
- Analytical standard for Palmitoylethanolamide.
- Intended for research and analytical applications.
- Can be used for preventing virus infection of the respiratory tract.
- High purity of 99.86%.
- Available in multiple quantities for various research needs.
- Suitable for qualitative, quantitative, and methodological research experiments in HPLC, GC, and MS.
Medchemexpress LLC B7-H2/ICOSLG Mouse 500ug
B7-H2/ICOSLG is an important ligand of the T cell receptor ICOS and mediates immune responses It acts as a costimulatory signal promoting T and B cell proliferation cytokine secretion and plasma cell differentiation B7-H2/ICOSLG Protein Mouse (HEK293 His) is the recombinant mouse-derived B7-H2/ICOSLG protein expressed by HEK293 with C-His labeled tag
Medchemexpress LLC MCC950 | 210826-40-7 | 99.8% | 200 MG
MCC950 is a potent and selective NLRP3 inhibitor, with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs. It blocks canonical and non-canonical NLRP3 activation at nanomolar concentrations. This product is for research use only.
- Potent and selective NLRP3 inhibitor
- Blocks canonical and non-canonical NLRP3 activation
- Specifically inhibits NLRP3, not AIM2, NLRC4, or NLRP1
- Reduces interleukin-1β (IL-1β) production
- Attenuates the severity of experimental autoimmune encephalomyelitis (EAE)
Apexbio Technology LLC Tebuconazole 107534-96-3 200mg
Tebuconazole (CAS 107534-96-3) is a small-molecule inhibitor targeting CYP51 a key enzyme in fungal sterol biosynthesis It modulates CYP51 activity to regulate sterol production within fungal cells Tebuconazole exerts its biological activity primarily through inhibition of CYP51 In cell-based assays tebuconazole demonstrates inhibitory activity with an IC50 value of 0 9 M against CaCYP51 from Candida albicans and 1 3 M against truncated human 60HsCYP51 Additionally in HepG2 cells tebuconazole induces lipid accumulation and oxidative stress and in mammary epithelial MAC-T cells it reduces proliferation and induces endoplasmic reticulum stress-mediated apoptosis Based on these pharmacological properties tebuconazole holds research potential in studies of fungal sterol biosynthesis cellular stress response pathways and apoptosis mechanisms
Medchemexpress LLC Finasteride | 98319-26-7 | MFCD00869737 | 100.0% | 372.54 | 200 MG
Finasteride is an orally active and competitive 5α-reductase inhibitor primarily targeting type II 5α-reductase. It works by blocking the conversion of testosterone into dihydrotestosterone (DHT), thereby reducing DHT levels in prostate cells and scalp hair follicles. This compound is used in research for conditions such as benign prostatic hyperplasia (BPH) and androgenic alopecia.
- Orally active and competitive 5α-reductase inhibitor
- Exhibits high affinity for type II 5α-reductase enzyme
- Reduces prostatic size and increases urine flow rate
- Promotes hair growth and prevents hair loss
- Suitable for research on benign prostatic hyperplasia (BPH)
- Suitable for research on androgenic alopecia
- Suppresses DHT levels in plasma and prostate
Medchemexpress LLC Amisulpride | 71675-85-9 | MFCD00866691 | 99.8% | C17H27N3O4S | 200 MG
Amisulpride is a racemic (50:50) mixture of R-Amisulpride and S-Amisulpride. It acts as a dopamine D2/D3 receptor antagonist with Ki values of 2.8 nM for human dopamine D2 and 3.2 nM for human dopamine D3 receptors. Amisulpride also functions as a 5-HT7 receptor antagonist with a Ki of 44 nM, making it suitable for use in psychiatric research.
- Racemic mixture
- Dopamine D2/D3 receptor antagonist
- 5-HT7 receptor antagonist
- Suitable for psychiatric research
- D3 receptor Ki: 3.2 nM
- Human D2 receptor Ki: 2.8 nM
- 5-HT7 receptor Ki: 44 nM
- Inhibits quinpirole-elicited [3H]thymidine incorporation
- Increases dopamine release from rat striatum slices
- Increases dopamine synthesis in rat striatum and limbic system
- Increases extracellular dopamine levels
- Decreases striatal ACh levels
- Increases duration of swimming behavior
Apexbio Technology LLC Iniparib (BSI-201) 160003-66-7 200mg
Iniparib (BSI-201) (CAS 160003-66-7) is a small-molecule inhibitor initially characterized as targeting poly(ADP-ribose) polymerase-1 (PARP1) It is designed to inhibit PARP1 by promoting oxidation of zinc finger motifs leading to zinc ejection and suppression of enzyme activity Iniparib exerts its biological activity primarily through metabolism into a C-nitroso intermediate which modifies cysteine residues in multiple proteins In cellular assays Iniparib demonstrates growth-inhibitory activity with reported IC50 values approximately ranging from 40 to 100 M in cancer cell lines Based on these pharmacological properties Iniparib holds research potential in oncology studies particularly in treatment-resistant and solid tumor models
Medchemexpress LLC Kaempferol | 520-18-3 | MFCD00004543 | 99.9% | C15H10O6 | 200 MG
Kaempferol is a naturally occurring flavonoid found in various edible plants. This compound functions as an estrogen receptor alpha inhibitor in breast cancer cells and promotes apoptosis in glioblastoma and lung cancer cells through MEK-MAPK activation. It is recognized as a human endogenous metabolite.
- Inhibits estrogen receptor alpha expression in breast cancer cells.
- Induces apoptosis in glioblastoma and lung cancer cells.
- Demonstrates anti-inflammatory activity.
- Exhibits antioxidant activity in human HepG2 cells.
- Shows antiproliferative activity against certain human cancer cell lines.
- Displays antiallergic activity.
- Demonstrates antiviral activity against influenza A virus.
- Inhibits melanogenesis.
- Inhibits procoagulant activity.
- Induces osteoclast apoptosis.
- Exhibits antiaggregatory activity in human platelets.
Medchemexpress LLC Cisapride | 81098-60-4 | 99.9% | C23H29ClFNO4 | 200 MG
Cisapride is an orally active 5-HT4 receptor agonist with an EC50 value of 140 nM. It is also a hERG blocker with an IC50 value of 9.4 nM. This gastroprokinetic agent stimulates gastrointestinal motor activity and is intended for research use only.
- Orally active 5-HT4 receptor agonist
- hERG blocker
- Stimulates gastrointestinal motor activity
- Suitable for high-speed applications
- Available in various solid pack sizes
TARGETMOL CHEMICALS INC Bucladesine sodium 200MG
Also available in 2 g, 1 mL, 25 mg, 50 mg, 100 mg, 500 mg and bulk. Please contact Fisher for quotes. Bucladesine sodium (DC2797) is a cAMP analog with cell-permeable properties. Bucladesine sodium is also a cAMP-dependent protein kinase (PKA) activator and a phosphodiester (PDE) inhibitor. Bucladesine sodium has anti-inflammatory activity. Purity 98.34%
Medchemexpress LLC Olmutinib | 1353550-13-6 | 99.5% / 99.9% | 486.59 | 200 MG
Olmutinib is an orally active and irreversible third-generation EGFR tyrosine kinase inhibitor. It binds to a cysteine residue near the kinase domain and is used for Non-Small Cell Lung Cancer (NSCLC). This product is for research use only.
- Orally active
- Irreversible third-generation EGFR tyrosine kinase inhibitor
- Binds to a cysteine residue near the kinase domain
- Used for Non-Small Cell Lung Cancer (NSCLC)
- For research use only